诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVS 诺华

未开盘 06-17 16:00:00 EDT

150.88

-0.05

-0.03%

盘后150.88

+0.000.00%

16:15 EDT

最高152.57	最低150.20	成交量166.49万
今开151.42	昨收150.93	日振幅1.57%
总市值2,879亿	流通市值2,740亿	总股本19.08亿
成交额2.52亿	换手率0.09%	流通股本18.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":150.88,"timestamp":1781726400000,"preClose":150.93,"halted":0,"volume":1664884,"hourTrading":{"tag":"盘后","latestPrice":150.88,"preClose":150.88,"latestTime":"16:15 EDT","volume":9520,"amount":1436379.4277,"timestamp":1781727320108,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0003312794010469182,"floatShares":1816000000,"shares":1907999999,"eps":6.980982,"marketStatus":"未开盘","change":-0.05,"latestTime":"06-17 16:00:00 EDT","open":151.42,"high":152.57,"low":150.2,"amount":252003078,"amplitude":0.015703,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.980982,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781769600000},"marketStatusCode":0,"adr":1,"adrRate":1,"exchange":"NYSE","adjPreClose":150.93,"dividendRate":0.030926,"preHourTrading":{"tag":"盘前","latestPrice":151.43,"preClose":150.92,"latestTime":"09:29 EDT","volume":9087,"amount":1377482.8821,"timestamp":1781702999999,"change":0.51,"changeRate":0.003379,"amplitude":0.009144},"postHourTrading":{"tag":"盘后","latestPrice":150.88,"preClose":150.88,"latestTime":"16:15 EDT","volume":9520,"amount":1436379.4277,"timestamp":1781727320108,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0383958816506467,"impliedVol":0.2402,"impliedVolPercentile":0.512},"requestUrl":"/m/hq/s/NVS","defaultTab":"news","newsList":[{"id":"2643756361","title":"摩根大通：生物药企融资回暖 大型药企行业并购优先级高于独立IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756361","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643756361?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:21","pubTimestamp":1781605294,"startTime":"0","endTime":"0","summary":"多数本土生物科技企业采取双轨策略，同步筹备 IPO、对接药企收购资源，不少企业上市落地前完成并购交割。头部药企偏好数十亿美金中型补充式并购，近期葛兰素史克斥资 106 亿美元收购肿瘤药企 Nuvalent，打破中小型并购定价惯例。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301588","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0820562030.AUD","GSKH","LU2211815571.USD","IE00BJJMRZ35.SGD","LU1548497426.USD","LU1629891620.HKD","LU2357627491.SGD","BK4504","NVS","SG9999002224.SGD","LU1496350502.SGD","JPMO","IE00B3S45H60.SGD","GSK","LU0689472784.USD","LU0238689110.USD","LU1261432733.SGD","LU2237443622.USD","LU0265550946.USD","GSK.UK","IE0009355771.USD","JPX","LU2592432038.USD","LU1894683348.USD","159839","IE00B2B36J28.USD","IE0034235303.USD","LU0070302665.USD","IE00BKDWB100.SGD","LU1064131342.USD","LU2505996509.AUD","LU1366192091.USD","PGF","BK4578","LU0211331839.USD","LU0942090050.USD","LU0964807845.USD","IE00B1XK9C88.USD","LU2357305700.SGD","LU0251132253.USD","JPO","LU0310799852.SGD","IE00BYXW3230.USD","JPM","LU0976567544.SGD","IPOS","LU0640476718.USD","LU0215105999.USD","LU0345769128.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119078937","title":"异动解读｜诺华盘前上涨3.11%，多项管线利好密集释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1119078937","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119078937?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:47","pubTimestamp":1781178451,"startTime":"0","endTime":"0","summary":"6月11日，诺华盘前上涨3.11%，报152.71美元/股，成交额113.54万美元。消息面上，诺华近期利好密集：公司宣布其肌营养不良实验性疗法del-brax的I/II期研究达到主要终点及关键次要终点；同日，诺华与Orionis Biosciences达成总额超14亿美元的分子胶药物合作；此外，泰菲乐联合迈吉宁新增适应症获中国国家药监局批准，用于BRAF V600E突变阳性的分化型甲状腺癌治疗。多重管线进展叠加，提振市场对公司研发管线价值的预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440345","title":"诺华泰菲乐联合迈吉宁新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440345","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642440345?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:13","pubTimestamp":1781086380,"startTime":"0","endTime":"0","summary":"南方财经6月10日电，诺华公司今日宣布，其双靶向联合治疗药物泰菲乐?（甲磺酸达拉非尼胶囊）联合迈吉宁?（曲美替尼片），于日前获国家药品监督管理局批准新增适应症，用于治疗BRAFV600E突变阳性、放射性碘难治或不适用、且血管内皮生长因子酪氨酸激酶抑制剂（VEGFR-TKI）治疗失败的局部晚期或转移性分化型甲状腺癌成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606103766815757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BJT1NW94.SGD","LU0070302665.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4588","BK4585","IE00BJJMRZ35.SGD","NVS","IE00B4R5TH58.HKD","IE0002141913.USD","IE0009355771.USD","BK4532","BK4007","LU0320765489.SGD","LU0211331839.USD","BK4578","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169307619","title":"异动解读｜诺华盘中上涨3.13%，Cosentyx三期试验数据积极叠加板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1169307619","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169307619?lang=zh_cn&edition=full","pubTime":"2026-06-05 03:21","pubTimestamp":1780600897,"startTime":"0","endTime":"0","summary":"6月5日，诺华盘中上涨3.13%，报148.15美元/股，成交额2.74亿美元。消息面上，诺华近日公布其核心产品Cosentyx在多发性风湿性肌痛（PMR）三期临床试验中的最新数据，显示该药物在持续缓解率方面相较对照组取得了具有统计学意义和临床意义的显著差异。此外，诺华在ASCO年会上公布的新型放射性药物治疗前列腺癌的早期临床数据亦表现强劲，为公司管线增添增长预期。板块方面，制药行业整体走强，个股中默沙东涨4.57%，诺和诺德涨4.26%，礼来涨4.13%，强生涨2.24%，辉瑞涨1.38%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186950476","title":"异动解读｜诺华盘中下跌3.06%，报145.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186950476","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186950476?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:14","pubTimestamp":1780323242,"startTime":"0","endTime":"0","summary":"6月1日，诺华盘中下跌3.06%，报145.04美元/股，成交额4396.47万美元。诺华所在的制药行业中，板块整体承压，个股中，施贵宝跌3.33%，默沙东跌2.75%，礼来跌2.19%，辉瑞跌1.91%，强生跌1.66%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089097","title":"博腾股份斯洛文尼亚项目陷争议 诺华索赔5470万欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089097","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635089097?lang=zh_cn&edition=full","pubTime":"2026-05-15 19:36","pubTimestamp":1778845013,"startTime":"0","endTime":"0","summary":"5月13日，博腾股份（300363.SZ）公告披露，其位于斯洛文尼亚的研发生产基地项目与Novartis（简称“诺华”）产生重大争议。诺华方面要求其在90天内搬离并保留合计约5470万欧元（约合人民币4.3亿元）的索赔权。博腾股份表示不认可诺华主张，公司及斯洛文尼亚项目全资子公司PSI尚未收到诺华已提起正式诉讼程序的通知。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739110668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4532","FXE","BK4585","IE00B4R5TH58.HKD","LU0211331839.USD","300363","LU0320765489.SGD","IE00B2B36J28.USD","NVS","BK4578","LU0070302665.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE0009355771.USD","BK4588","BK4007","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0208291251.USD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635722124","title":"累计投入4.48亿元 博腾股份欧洲研发生产基地遭诺华解约","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722124","media":"中国经营报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635722124?lang=zh_cn&edition=full","pubTime":"2026-05-15 07:27","pubTimestamp":1778801222,"startTime":"0","endTime":"0","summary":"5月13日，博腾股份（300363.SZ）披露，其位于斯洛文尼亚的研发生产基地遭到诺华公司（Novartis）的单方面解约，诺华公司要求其在90天内搬离。历史公告显示，这个研发生产基地是博腾股份在欧洲布局的首个研发生产基地，投资金额为5000万欧元（当时折合人民币约3.5亿元）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153737904337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4007","LU0070302665.USD","BK4578","BK4532","LU0211331839.USD","LU0320765489.SGD","BK4588","IE0002141913.USD","BK0028","IE0009355771.USD","300363","LU0208291251.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635794643","title":"股价跌停！博腾股份海外项目遭诺华单方面解约","url":"https://stock-news.laohu8.com/highlight/detail?id=2635794643","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635794643?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:09","pubTimestamp":1778746140,"startTime":"0","endTime":"0","summary":"5月13日晚间，国内领先的合同研发生产组织（CDMO）博腾股份（300363.SZ）的一纸公告，为其筹划近四年的欧洲市场布局蒙上了一层厚重的阴霾。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143737441846.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737441846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU0070302665.USD","BK4585","IE0009355771.USD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4578","BK4532","IE00BFTCPJ56.SGD","NVS","BK0028","BK4007","300363","IE00B4R5TH58.HKD","LU0211331839.USD","LU0320765489.SGD","BK0239","IE00BJJMRZ35.SGD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119830","title":"跨国药企业绩大爆发，集体加仓中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119830","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633119830?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:19","pubTimestamp":1778141940,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　2026年第一季度，全球制药巨头的业绩版图再度刷新。　　有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。默沙东与其他跨国药企一道，已将“加注中国创新”视为战略性防御与进攻并存的长期解法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1929549753.HKD","LU2125154935.USD","LU0289739699.SGD","LU2361044865.SGD","SG9999001440.SGD","IE00BN8TJ469.HKD","NVOX","LU2361045086.USD","IE00BJJMRZ35.SGD","LU2468319806.SGD","BK4007","LU1941712264.USD","NVOH","BK4550","LU0211331839.USD","LU1941712348.USD","SG9999014567.USD","LU2112291526.USD","SG9999001176.USD","SG9999002224.SGD","SG9999013999.USD","EURmain","BK4588","LU0203347892.USD","LU1066051811.HKD","LU1023059063.AUD","LU1035773651.USD","LU0942090050.USD","LU1989772923.USD","LU0130102774.USD","LU2491049909.HKD","LU1069347547.HKD","LU1291159041.SGD","SG9999001176.SGD","LU1061106388.HKD","FXE","EUO","LU1093756325.SGD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1585245621.USD","LU2089984988.USD","IE000M9KFDE8.USD","IE00B2B36J28.USD","LU0006306889.USD","LU0965509101.SGD","SG9999002232.USD","LU2357627491.SGD","LU0070302665.USD","SG9999014575.USD","BK4532","SG9999015358.SGD","LU2360032135.SGD","BK4533","LU0058720904.USD","LU0320765646.SGD","LU1116320901.HKD","LU1934455194.USD","IE00BZ1G4Q59.USD","LU1917777945.USD","SG9999015341.SGD","MRK","LU2023250504.SGD","LU0265550359.USD","MEURmain","LU0266013472.USD","LU2491050154.USD","LU0432979614.USD","LU0980610538.SGD","LU1037948541.HKD","LU2361044949.HKD","LU0098860793.USD","LU0130517989.USD","LU0965508806.USD","LU0965509010.AUD","LU0122379950.USD","BMY","LU0203345920.USD","LU0648001328.SGD","LU2125154778.USD","LU1093756168.USD","LU1162221912.USD","BK4585","LU0265550946.USD","LU0106261372.USD","LU1201861249.SGD","LU0868494617.USD","IE00BJT1NW94.SGD","LU0477156953.USD","SG9999014559.SGD","LU1057294990.SGD","SNY","LU0965509283.SGD","IE00BLSP4452.SGD","BK4599","LLY","LU0154236417.USD","AZN","LU0320765489.SGD","IE00B1BXHZ80.USD","LU1934455277.USD","IE0002141913.USD","LU1989772840.SGD","LU1989771016.USD","LU0985320562.USD","IE00BKVL7J92.USD","LU1037948897.HKD","LU2106854487.HKD","LU1983299246.USD","IE00BSNM7G36.USD","LU0208291251.USD","SG9999014542.SGD","LU1066051498.USD","LU1116320737.USD","LU0238689110.USD","LU0861579265.USD","LU1066051225.USD","LU1066053197.SGD","LU1934455863.HKD","BK4534","LU2023250843.SGD","BK4516","BK4559","LU0234572021.USD","LU1699723380.USD","LU2324357040.USD","LU1974910355.USD","IE00BLSP4239.USD","LU0859254822.USD","LU1430594728.SGD","LU0868494708.USD","IE0009355771.USD","LU1571399168.USD","LU2491050071.SGD","NVO","LU2461242641.AUD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145136092","title":"诺华Q1销售净额131.1亿美元，不及市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1145136092","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145136092?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:50","pubTimestamp":1777355455,"startTime":"0","endTime":"0","summary":"4月28日，$诺华(NVS)$夜盘跌超3%！第一季度销售净额131.1亿美元，市场预估133.6亿美元；第一季度核心净利润37.9亿美元，市场预估39.9亿美元；第一季度核心运营利润49.0亿美元，市场预估51.8亿美元；第一季度核心每股收益1.99美元，市场预估2.10美元。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"fe641e10371c88c59b8e1ccc5404fa38","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺华Q1销售净额131.1亿美元，不及市场预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","BK4532","IE00BJJMRZ35.SGD","BK4585","IE00B4R5TH58.HKD","BK4588","BK4007","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0208291251.USD","IE00B2B36J28.USD","LU0211331839.USD","LU0320765489.SGD","NVS","IE0009355771.USD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115331145","title":"由于仿制药冲击严重，诺华一季度利润未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1115331145","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115331145?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:18","pubTimestamp":1777353502,"startTime":"0","endTime":"0","summary":"瑞士制药商 $诺华(NVS)$ 诺华（Novartis）周二公布，其第一季度核心营业利润低于市场预期，原因是其畅销心脏药物Entresto面临美国仿制药竞争，对销售造成压力。经特殊项目调整后的季度集团营业利润为49亿美元，低于Visible Alpha引用的分析师平均预期约51亿美元。","market":"us","thumbnail":"https://community-static.tradeup.com/news/374dbbb7be17d6f7bf0b1b2658569853","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/374dbbb7be17d6f7bf0b1b2658569853"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"fe641e10371c88c59b8e1ccc5404fa38","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"诺华第一季度利润受美国仿制药冲击而下滑","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2630532966","title":"诺华一季度销售净额131.13亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630532966","media":"第一财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630532966?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:08","pubTimestamp":1777352939,"startTime":"0","endTime":"0","summary":"【诺华一季度销售净额131.13亿美元】诺华发布财报，2026年第一季度销售净额131.13亿美元，营业利润42.35亿美元，核心每股收益1.99美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721992511.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721992511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4532","BK4585","IE0009355771.USD","LU0208291251.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","BK4578","BK4588","LU0211331839.USD","IE0002141913.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629152808","title":"诺华(NVS)抗疟婴儿药获世卫预认证 以非营利方式供应疫区","url":"https://stock-news.laohu8.com/highlight/detail?id=2629152808","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629152808?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:12","pubTimestamp":1777018331,"startTime":"0","endTime":"0","summary":"世卫组织相关负责人表示，目前尚无专门针对该体重区间婴幼儿单纯性疟疾的治疗药物，该复方制剂填补了这一空白。诺华在声明中称，将在疟疾流行地区以非营利方式提供该治疗药物，助力提升疫区婴幼儿抗疟治疗可及性。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299641","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BK4588","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE0009355771.USD","LU0070302665.USD","BK4532","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4007","LU0208291251.USD","LU0211331839.USD","NVS","IE0002141913.USD","BK4585","BK4578","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627447062","title":"Anthropic任命诺华CEO瓦斯·纳拉西姆汉加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2627447062","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627447062?lang=zh_cn&edition=full","pubTime":"2026-04-14 23:06","pubTimestamp":1776179160,"startTime":"0","endTime":"0","summary":"据报道，人工智能初创公司Anthropic已任命诺华首席执行官瓦斯·纳拉西姆汉 为其董事会成员，这是该公司数月内第二次增补董事会成员。　　此次任命正值Anthropic积极推进IPO计划并进一步拓展医疗保健领域业务之际。　　Anthropic联合创始人丹妮拉·阿莫代伊在一份声明中表示，纳拉西姆汉曾负责监督超过35种创新药物的开发与审批工作，积累了“在监管最为严格的行业之一”的丰富经验。　　此次董事会人事变动是Anthropic加速进军医疗健康领域的最新举措。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-14/doc-inhunttt8941455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0070302665.USD","BK4532","IE00BJJMRZ35.SGD","BK4585","IE00B4R5TH58.HKD","BK4588","BK4007","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0208291251.USD","IE00B2B36J28.USD","LU0211331839.USD","LU0320765489.SGD","NVS","IE0009355771.USD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626185568","title":"诺华(NVS)宣布扩大全球医疗公益 偏远地区推心脑血管与癌症救治","url":"https://stock-news.laohu8.com/highlight/detail?id=2626185568","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626185568?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:21","pubTimestamp":1775730088,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华制药(NVS)周四宣布，将扩大全球公益项目，面向偏远地区开展心脏病与癌症患者的筛查和治疗。项目覆盖国家将由目前 11 个，增至 2030 年超 30 个，同时纳入美国五座城市。在多国慢性病公共卫生投入放缓的背景下，诺华表示将重点覆盖医疗体系中被忽视的群体。项目将联合当地社区组织、卫生部门及企业，提升预防与早诊服务可及性，优化诊疗转诊与后续康复流程，推动基层慢病规范管理。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298971","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","NVS","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","159891","IE0009355771.USD","IE0002141913.USD","LU0070302665.USD","BK4007","BK4588","LU0320765489.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4585","BK4578","LU0211331839.USD","IE00B4R5TH58.HKD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622487680","title":"诺华拟斥高达20亿美元收购生技公司Excellergy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622487680","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622487680?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:43","pubTimestamp":1774626210,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华将斥高达20亿美元收购生技公司Excellergy，交易预计将于今年下半年完成，但需满足包括获得监管部门批准在内的各项条件。收购协议将包括首期付款及里程碑付款。透过今次交易，诺华将收购Excellergy的候选药物Exl-111，这是一种抗IgE抗体，目前处于早期测试阶段，可补充公司现有的过敏产品组合。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298472","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","BK4578","BK4585","LU0208291251.USD","LU0211331839.USD","NVS","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4007","IE00BJT1NW94.SGD","LU0070302665.USD","LU0320765489.SGD","BK4588","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845105","title":"诺华制药(NVS.US)20亿美元收购Excellergy 加码食物过敏与免疫疾病赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845105","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622845105?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:36","pubTimestamp":1774597007,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药已同意以高达20亿美元的价格收购生物技术公司Excellergy Inc.，此项交易将强化其在食物过敏及其他免疫疾病治疗领域的产品组合。此次收购的核心资产是Excellergy公司研发的创新候选药物Exl-111。从行业影响来看，Excellergy的加入将使诺华制药在过敏性疾病领域拥有更具差异化的产品组合。此外，诺华制药还于去年10月宣布了其最大规模投资之一——以120亿美元收购Avidity Biosciences公司，随后又陆续达成多项针对过敏性疾病及乳腺癌药物的交易合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0009355771.USD","NVS","BK4588","BK1191","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","LU0320765489.SGD","IE00BJJMRZ35.SGD","BK4007","BK4585","BK1574","IE00B2B36J28.USD","LU0070302665.USD","BK4532","IE00BJT1NW94.SGD","IE0002141913.USD","BK4578","LU0211331839.USD","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622302684","title":"阿里健康与诺华达成数字化慢病合作 共建慢性荨麻疹院外管理新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2622302684","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622302684?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:37","pubTimestamp":1774427820,"startTime":"0","endTime":"0","summary":"【阿里健康与诺华达成数字化慢病合作 共建慢性荨麻疹院外管理新模式】记者3月25日获悉，阿里健康与诺华制药宣布在慢性自发性荨麻疹（CSU）领域达成数字化慢病合作。双方将围绕诺华旗下全球首个口服荨麻疹靶向药瑞米布替尼片（商品名：瑞普多），依托阿里健康的数字化平台能力，提供从疾病科普、用药指导到全周期健康管理的整合式服务。阿里健康依托其长期深耕的“全周期慢病管理体系”，为患者打造一个“院外第二诊室”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684062712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4007","IE00B2B36J28.USD","BK1617","BK1142","BK4588","IE0002141913.USD","IE00BFTCPJ56.SGD","BK1247","BK1584","IE00B4R5TH58.HKD","BK4532","BK4585","BK1501","BK1589","00241","BK4578","LU0211331839.USD","BK1615","BK1515","BK1610","BK1591","BK1502","LU0320765489.SGD","NVS","LU0208291251.USD","BK1571","LU0070302665.USD","BK1189","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063596","title":"诺华国际业务部总裁：中国是引入创新和谋求合作的绝佳之地","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063596","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621063596?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:39","pubTimestamp":1774345140,"startTime":"0","endTime":"0","summary":"自2015年以来，在政策、人才、资本等多重力量的推动下，中国医药创新取得长足发展，创新活力和成果引发全球瞩目。2026年是“十五五”开局之年，“十五五”规划纲要提出，加快生物医药等战略性新兴产业发展。2026年的政府工作报告也提出“推动创新药高质量发展”，并首次将生物医药列入“新兴支柱产业”。宏观政策信号持续释放，产业定位进一步提升，中国医药创新有望迎来新的发展窗口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682667347.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682667347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4532","BK4585","IE0009355771.USD","LU0208291251.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","BK4578","BK4588","LU0211331839.USD","IE0002141913.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621236627","title":"诺华万思瀚：人工智能等新兴技术正进一步放大医疗创新的影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2621236627","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621236627?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:07","pubTimestamp":1774231620,"startTime":"0","endTime":"0","summary":"　　中国发展高层论坛2026年年会于3月22日至23日在北京召开，本届论坛主题为“‘十五五’的中国：高质量发展与共创新机遇”。诺华公司首席执行官万思瀚在“健康中国2030”与大健康产业发展专题研讨会上重点探讨了两个核心议题：医疗健康领域创新投资的重要性，以及如何确保创新在未来持续在中国发展以应对挑战。　　万思瀚强调，人工智能等新兴技术正进一步放大医疗创新的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/meeting/2026-03-23/doc-inhrxvtt5381419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4532","161631","IE00BJJMRZ35.SGD","IE0009355771.USD","IE0002141913.USD","BK4007","LU0320765489.SGD","LU0070302665.USD","LU0208291251.USD","LU0211331839.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","159891","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4578","BK4588","NVS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":0.0186},{"period":"1month","weight":0.0116},{"period":"3month","weight":0.0182},{"period":"6month","weight":0.1089},{"period":"1year","weight":0.2961},{"period":"ytd","weight":0.0944}],"compareEarnings":[{"period":"1week","weight":0.0214},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.123},{"period":"6month","weight":0.0887},{"period":"1year","weight":0.24},{"period":"ytd","weight":0.0866}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日根据瑞士法律注册成立，为股份公司。公司是一家创新医药公司，从事研究、开发、制造、分销、营销和销售范围广泛的医药产品。它专注于核心治疗领域，包括心血管、肾脏和代谢疾病、免疫学、神经科学和肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.007884},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.004502},{"month":3,"riseRate":0.5,"avgChangeRate":-0.002232},{"month":4,"riseRate":0.692308,"avgChangeRate":0.016763},{"month":5,"riseRate":0.692308,"avgChangeRate":0.0095},{"month":6,"riseRate":0.592593,"avgChangeRate":0.011729},{"month":7,"riseRate":0.692308,"avgChangeRate":0.011407},{"month":8,"riseRate":0.423077,"avgChangeRate":0.001152},{"month":9,"riseRate":0.692308,"avgChangeRate":0.009673},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.013123},{"month":11,"riseRate":0.615385,"avgChangeRate":0.016411},{"month":12,"riseRate":0.692308,"avgChangeRate":0.020635}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}